Loading...
VERV logo

Verve Therapeutics, Inc.Informe acción NasdaqGS:VERV

Capitalización bursátil US$991.5m
Precio de las acciones
US$11.13
US$15.11
26.3% infravalorado descuento intrínseco
1Y48.8%
7D1.6%
1D
Valor de la cartera
​
Ver

Verve Therapeutics, Inc.

Informe acción NasdaqGS:VERV

Capitalización de mercado: US$991.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Verve Therapeutics (VERV) Resumen de Acciones

Verve Therapeutics, Inc, una empresa en fase clínica, desarrolla medicamentos de edición génica para pacientes con el fin de tratar enfermedades cardiovasculares en Estados Unidos. Saber más

Análisis fundamental de VERV
Puntuación del snowflake
Valoración0/6
Crecimiento futuro0/6
Rendimiento pasado0/6
Salud financiera6/6
Dividendos0/6

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 15.7% al año durante los próximos 3 años

Precio de las acciones muy volátil durante los últimos 3 meses en comparación con el mercado US

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años


VERV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de Verve Therapeutics, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Verve Therapeutics
Precios históricos de las acciones
Precio actual de la acciónUS$11.13
Máximo en las últimas 52 semanasUS$11.41
Mínimo de 52 semanasUS$2.86
Beta2.24
Cambio en 1 mes-0.36%
Variación en 3 meses93.23%
Cambio de 1 año48.80%
Variación en 3 años-59.60%
Variación en 5 añosn/a
Variación desde la OPV-65.13%

Noticias y actualizaciones recientes

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha
Artículo de análisis • May 28

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Verve Therapeutics, Inc. ( NASDAQ:VERV ) share price has dived 26% in the last...
Artículo de análisis • May 19

News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Apr 16

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'

Summary VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102’s development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV’s pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly. And from a valuation perspective, the shares are cheaper than the first time I covered it. All while making great progress with its pipeline. So, ultimately, I think VERV remains a high-risk, long-term play in gene editing. But its risk-reward profile now seems to justify a “Buy” rating. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts

Summary Company received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. The switch to the Gal-NAc LNP delivery system aims to improve safety, avoiding clinical abnormalities observed with VERVE-101. Key upcoming catalysts include initial phase 1b Heart-2 data in Q2 2025, final dose-escalation data, and potential Eli Lilly opt-in for PCSK9 inhibitor program in the 2nd half of 2025. Atherosclerotic Cardiovascular Disease, in the 7 Major Markets, is expected to reach $30.6 billion by 2035. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2

Summary Verve Therapeutics' stock remains a "Buy" despite recent setbacks, including the retirement of its Chief Medical Officer and the termination of a collaboration with Vertex. Verve's gene-editing programs aim to transform cardiovascular disease treatment by permanently lowering cholesterol through a one-time intravenous infusion, offering significant therapeutic and commercial potential. The upcoming data readout for Verve-102 in 2025 is crucial; success could attract Eli Lilly's partnership, while failure may question the entire base editing approach. Despite leadership changes and challenges, Verve's innovative approach and potential for groundbreaking treatments justify a high-risk, high-reward investment strategy. Read the full article on Seeking Alpha
Artículo de análisis • Dec 08

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 30

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with single-course gene editing, despite facing significant challenges and setbacks in clinical trials. The company's lead assets, VERVE-101 and VERVE-102, target the PCSK9 gene to lower LDL-C levels, but safety issues have hindered progress. Verve-102, using a different delivery technology, is now the focus, with initial data expected in 1H25, presenting a crucial milestone for investors. Partnerships with Eli Lilly, Beam Therapeutics, and Vertex offer potential financial support and validation, but Verve remains a high-risk, high-reward investment. Read the full article on Seeking Alpha
Artículo de análisis • Aug 10

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest second-quarter results with some...
Artículo de análisis • Jul 12

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jun 13

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Summary Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD. VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to lower ASCVD risk. Verve's leading programs, VERVE-101 and VERVE-102, target heterozygous familial hypercholesterolemia (HeFH), with VERVE-101 in clinical trials and VERVE-102 in the IND-enabling stage. Financially, Verve has a strong cash position, with $606.3 million in liquidity and a cash runway of approximately 3.5 years. VERV's research is in the early stages, making it a speculative investment, but it is worth adding to a watchlist as research progresses. Read the full article on Seeking Alpha
Artículo de análisis • May 14

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Artículo de análisis • May 12

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest first-quarter results with some...
Seeking Alpha • Apr 03

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward with another PCSK9 inhibitor known as VERVE-102 where the phase 1b heart-2 study is expected to begin any day now in Q2 2024. VERVE-102 could be a major change in structure because it has two distinct features compared to its predecessor, which are a different ionizable lipid and the GalNAc delivery system. Partnership with Eli Lilly remains in place for now, despite VERVE-101 enrollment being paused. Read the full article on Seeking Alpha
Artículo de análisis • Feb 28

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 13

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with gene therapy. Recent VERVE-101 data shows LDL-C reduction comparable to existing drugs but with serious adverse events in two patients, raising safety concerns. Verve's financials show a solid runway with ~$600 million in liquid assets after a recent capital infusion, but ongoing and future trials will demand substantial funding. Recommendation: Sell. Despite proof-of-concept and a one-time treatment appeal, safety concerns and competitive landscape challenge its long-term valuation. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Vectoring In On Verve Therapeutics

Summary Verve Therapeutics aims to revolutionize treatment for cardiovascular disease through in vivo gene therapy using base editing technology. Their lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. Verve has partnerships with Beam Therapeutics, Eli Lilly, and Vertex Pharmaceuticals, and analysts have a positive outlook on the company. A full investment analysis around Verve Therapeutics stock is presented in the paragraphs below. Read the full article on Seeking Alpha
Artículo de análisis • Jun 07

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Feb 24

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Nov 09

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 20

Verve Therapeutics: Cathie Wood Adds To ARKK

Summary ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares. Company fits usual pattern with large losses and cash burn.

Rentabilidad de los accionistas

VERVUS BiotechsMercado US
7D1.6%2.1%-3.3%
1Y48.8%25.0%22.3%

Rentabilidad vs. Industria: VERV superó a la industria US Biotechs, que obtuvo un rendimiento del 25% el año pasado.

Rentabilidad vs. Mercado: VERV superó al mercado US, que obtuvo un rendimiento del 22.3% el año pasado.

Volatilidad de los precios

Is VERV's price volatile compared to industry and market?
VERV volatility
VERV Average Weekly Movement24.9%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: El precio de las acciones de VERV ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de VERV ha aumentado de 18% a 25% en el último año.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
2018274Sek Kathiresanwww.vervetx.com

Verve Therapeutics, Inc, una empresa en fase clínica, desarrolla medicamentos de edición genética para pacientes con el fin de tratar enfermedades cardiovasculares en Estados Unidos. Los productos candidatos de la empresa incluyen VERVE-101, que se está evaluando en el ensayo Heart-1, un ensayo clínico de fase 1b abierto, así como los cambios en la proteína PCSK9 en sangre y los niveles de LDL-C en pacientes con hipercolesterolemia familiar heterocigota (HeFH); VERVE-102, que se está evaluando en el ensayo Heart-2, un ensayo clínico abierto de fase 1b en pacientes adultos con HeFH y/o enfermedades coronarias prematuras; VERVE-201, que se dirige al ANGPTL3 y desactiva permanentemente el gen ANGPTL3 en el hígado; y VERVE-301, un candidato a desarrollo que utiliza un novedoso enfoque de edición génica in vivo para desactivar permanentemente el gen LPA en el hígado a fin de reducir los niveles de Lp(a) en sangre. Tiene un acuerdo de colaboración y licencia con Beam Therapeutics Inc; un acuerdo de desarrollo y opción con Acuitas Therapeutics, Inc; un acuerdo de licencia de tecnología lipídica con Novartis Pharma AG; Eli Lilly and Company; y un acuerdo de licencia de Cas9 con The Broad Institute y el President and Fellows of Harvard College.

Resumen de fundamentos de Verve Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Verve Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de VERV
Capitalización bursátilUS$991.46m
Beneficios(TTM)-US$181.01m
Ingresos (TTM)US$59.61m
16.7x
Ratio precio-ventas (PS)
-5.5x
Ratio precio-beneficio (PE)

¿Está VERV sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VERV
IngresosUS$59.61m
Coste de los ingresosUS$210.43m
Beneficio bruto-US$150.82m
Otros gastosUS$30.19m
Beneficios-US$181.01m

Últimos beneficios comunicados

Mar 31, 2025

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-2.03
Margen bruto-252.99%
Margen de beneficio neto-303.64%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado VERV a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2025/07/24 09:43
Precio de las acciones al final del día2025/07/24 00:00
Beneficios2025/03/31
Ingresos anuales2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Verve Therapeutics, Inc. está cubierta por 3 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Andrea NewkirkGoldman Sachs
Mitchell KapoorH.C. Wainwright & Co.
Dae Gon HaStifel, Equities Research